Oncology Today with Dr Neil Love

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:Introduction (0:00)Overview of Antibody-Drug Conjugates (ADCs) (2:07)Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)Currently Available ADCs for Gynecologic Cancer Management (26:37)Currently Available ADCs for Lung Cancer Management (44:07)Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)NCPD information and select publications

Featuring an interview with Dr Rana R McKay, including the following topics:Prostate Cancer Working Group (PCWG4) revised terminology (0:00)Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)Takeaways from the Phase III EMBARK study (19:36)Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics: Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)NCPD information and select publications

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00)Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00)Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: Introduction (0:00)Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)CME information and select publications

Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics: Introduction (0:00)Desmoid Tumors — Dr Gounder (2:58)Soft Tissue Sarcoma — Dr Riedel (28:29)CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00)Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38)Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20)CME information and select publications

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We’re Heading (0:00)First-Line Treatment of BRCA Wild-Type Disease (9:14)First-Line Treatment of BRCA-Mutant Disease (38:48)Novel Approaches (47:49)CME information and select publications

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:Introduction: Life After Radical Cystectomy (0:00)Muscle-Invasive Bladder Cancer — Prof Powles (9:15)Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)CME information and select publications

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00)Systemic Mastocytosis — Dr Hunter (9:33)Myelofibrosis — Dr Yacoub (29:40)CME information and select publications

Featuring perspectives from Dr Dana M Chase, Ms Sarah Karpen, Dr J Alejandro Rauh-Hain and Ms Jaclyn Shaver, moderated by Dr Chase, including the following topics:Introduction: Biology of Endometrial Cancer (EC) (0:00)First-Line Therapy for Advanced or Recurrent EC (14:15)Potential Benefits of PARP Inhibition Combined with Immunotherapy in Advanced EC (35:13)Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC (57:48)Other Nursing Considerations in the Care of Patients with Advanced EC (1:17:28)NCPD information and select publications

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:Introduction (0:00)Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51)CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:Introduction (0:00)Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics:Introduction (0:00)Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer (CRC) — Dr Ciombor (3:58)Other Recent Advances in CRC Management — Dr Strickler (32:57)CME information and select publications

Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics: Introduction (0:00)Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08)Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20)CME information and select publications

Featuring an interview with Prof Bernd Kasper, including the following topics: Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00)Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04)Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58)Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19)CME information and select publications

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O’Malley, including the following topics: Introduction (0:00)PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37)Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O’Malley (35:18)CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics: Introduction (0:00)Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52)Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20)CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)CME information and select publications

Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)Considerations with maintenance therapy for ES-SCLC (9:31)Considerations with immunotherapy for ES-SCLC (13:12)Curability of SCLC with systemic therapy (15:17)Data with chemoimmunotherapy for patients with poor performance status (25:55)Future developments in therapy for SCLC (30:11)Rapid fire: Small Cell 101 (35:45)CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00)Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics:Introduction (0:00)Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16)Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O’Malley (1:00:31)CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)CME information and select publications

Featuring perspectives from Dr Eileen M O’Reilly and Dr Philip A Philip, including the following topics:Introduction (0:00)Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27)Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O’Reilly (28:05)CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)CME information and select publications

Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.CME information and select publications

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Virginia Kaklamani from the UT Health San Antonio MD Anderson Cancer Center in San Antonio, Texas, discuss patient cases and review relevant data on the management of ER-positive, HER2-negative metastatic breast cancer.CME information and select publications

Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC.CME information and select publications

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.CME information and select publications

Prof Ramez N Eskander from UC San Diego Moores Cancer Center in California, Dr Bradley J Monk from Florida Cancer Specialists & Research Institute in West Palm Beach and Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, review the treatment landscape of antibody-drug conjugate–directed therapy for gynecologic cancers and review recently presented clinical findings from the SGO 2026 Annual Meeting on Women’s Cancer.CME information and select publications

Prof Bernd Kasper from the Mannheim Cancer Center in Mannheim, Germany, discusses recent updates on available and novel treatment strategies for desmoid tumors. CME information and select publications here.

Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center in Houston and Dr Anwaar Saeed from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, discuss key clinical trial data regarding the management of colorectal cancer.CME information and select publications here.

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications here.

Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year. CME information and select publications here.

Prof Nicoletta Colombo from the European Institute of Oncology IRCCS in Milan, Italy, Dr Alexander Olawaiye from the University of Pittsburgh School of Medicine in Pennsylvania, Dr Gottfried Konecny from the University of California, Los Angeles and Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discuss key clinical trial data surrounding the management of ovarian cancer, alongside clinical cases and questions.CME information and select publications here.

Dr Jaffer A Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel J Klempner from Massachusetts General Hospital in Boston review data supporting immunotherapy for gastroesophageal cancers and findings presented at the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer. CME information and select publications here.

Dr Floor J Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, and Dr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, discuss key clinical trial data, clinical cases and questions surrounding the management of endometrial cancer using immunotherapy. CME information and select publications here.

Dr Nikhil I Khushalani from the Moffitt Cancer Center in Tampa, Florida, discusses available and novel treatment strategies for nonmelanoma skin cancers.NCPD information and select publications here.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here.

Dr Aditya Bardia from the University of California Los Angeles and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the use of oral SERDs in the management of breast cancer. CME information and select publications here.

Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year. CME information and select publications here.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.

Dr Andrew J Armstrong from the Duke Cancer Institute in Durham, North Carolina, and Dr Scott T Tagawa from Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss the selection and sequencing of therapy for patients with prostate cancer and summarize major advances in the treatment landscape over the past year.CME information and select publications here.

Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.CME information and select publications here.

Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer.CME information and select publications here.

Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here.

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.